How did IBIO's Q2 2024 earnings compare to expectations?

iBio's Q2 2024 earnings report is not currently available. However, we can analyze the available data to provide insights into the company's performance.

1. **No Earnings Report for Q2 2024**: There are no available earnings reports for iBio's Q2 2024. This means that we do not have any financial data to compare against expectations for that quarter.
2. **Recent Financial Results**: The latest financial results available are for Q3 2024. iBio reported an earnings per share (EPS) of -$0.71 for the quarter, with no revenue reported.

|code|Ticker|Name|Date|Estimate EPS YoY|Estimate Revenue YoY|market_code|
|---|---|---|---|---|---|---|
|IBIO|IBIO.O|iBio|20230930|-3879.9999999999995|150|186|
|IBIO|IBIO.O|iBio|20240331|-343.2432432432432||186|

3. **Analyst Expectations**: Analysts had forecasted an EPS of -$99.82 for the entire FY2024, which includes Q2 2024. This suggests that the company's performance in Q2 was not an outlier, as the actual EPS for Q3 was closer to this expected figure.
4. **Stock Performance and Ratings**: Despite the negative earnings, iBio's stock has received positive ratings from Chardan Capital, which has a "Buy" rating and a $5.00 price target, indicating potential confidence in the company's future. However, StockNews.com has initiated coverage with a "sell" rating.

In conclusion, due to the unavailability of Q2 2024 earnings data, we cannot provide a direct comparison to expectations. However, the available Q3 2024 earnings report shows iBio with a negative EPS and no revenue, which aligns with analyst expectations for the FY2024 period. The mixed ratings from analysts reflect the complex landscape of iBio's current market position and future prospects.